The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Duloxetine for the Treatment of Fibromyalgia in Women: Pooled Results from Two Randomized, Placebo-Controlled Clinical Trials
Abstract
BACKGROUND: To assess the efficacy (in particular, in pain, functional impairment, and quality of life) and safety and tolerability (incidence of adverse events, discontinuation rates, changes in laboratory findings, and vital signs) of duloxetine in female patients with fibromyalgia. METHODS: Data were pooled from two placebo-controlled clinical trials of similar design (randomized, 12-week, and double-blind), comparing duloxetine 60 mg a day (q.d.) or 60 mg twice daily (b.i.d.) (n = 326) with placebo (n = 212), in women who met the American College of Rheumatology criteria for primary fibromyalgia. RESULTS: Compared with the patients receiving placebo, duloxetine-treated female patients demonstrated a significantly greater improvement in the Brief Pain Inventory (BPI) average pain severity score and in the Fibromyalgia Impact Questionnaire (FIQ) total score, beginning at week 1 and continuing through week 12 (p < 0.001). Duloxetine was superior to placebo on all efficacy measures, including mean tender point threshold, Clinical Global Impression of Severity, Patient Global Impression of Improvement, and average interference from pain scores. The duloxetine-treated group was superior to placebo on all quality of life and functional measures, including each domain of the Medical Outcomes Study Short Form-36 (SF-36). A direct treatment effect of duloxetine on pain reduction was demonstrated and shown to be independent of secondary improvement in mood (based on BPI average pain score). Significantly more duloxetine-treated patients reported treatment-emergent adverse events (296 [90.8%] duloxetine-treated and 165 [77.8%] placebo-treated, p < 0.001). Rates of serious adverse events were similar between duloxetine-treated and placebo-treated patients. CONCLUSIONS: The pooled results of these studies demonstrate that duloxetine is a safe and efficacious treatment for both the pain and functional impairment associated with fibromyalgia in female patients, while significantly improving quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The american college of rheumatology 1990 criteria for the classification of fibromyalgia
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330203 · Cited by 9,563
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624 · cited 1×
“…of duloxetine were conducted in patients with primary fibromyalgia, the first of which examined the safety and efficacy of duloxetine 60 mg twice daily (b.i.d.) in male and female patients 13 and the second of which evaluated duloxetine 60 mg once daily (q.d.) and 60 mg b.i.d. in female patients.”
Self-citationArnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471
Self-citationFibromyalgia Is Associated With Impaired Balance and Falls
Jones, K. D., Horak, F. B., Winters-Stone, K., Irvine, J. M., & Bennett, R. M. (2009) · JCR: Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e318190f991 · Cited by 162
Biology and therapy of fibromyalgia. New therapies in fibromyalgia.
Arnold (2006) · Arthritis Research & Therapy · doi:10.1186/ar1971 · Cited by 145
Cited by
Elevated insular glutamate in fibromyalgia is associated with experimental pain
Harris, R. E., Sundgren, P. C., Craig, A. D., Kirshenbaum, E., Sen, A., Napadow, V., & Clauw, D. J. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24849 · Cited by 328
Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews
Kroenke, K., Krebs, E. E., & Bair, M. J. (2009) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2008.12.006 · Cited by 307
Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct
MEASE, P., ARNOLD, L. M., CHOY, E. H., CLAUW, D. J., CROFFORD, L. J., GLASS, J. M., MARTIN, S. A., MOREA, J., SIMON, L., STRAND, C. V., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090367 · Cited by 256
Self-citationFibromyalgia Is Associated With Impaired Balance and Falls
Jones, K. D., Horak, F. B., Winters-Stone, K., Irvine, J. M., & Bennett, R. M. (2009) · JCR: Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e318190f991 · Cited by 162
Hsu, M. C., Schubiner, H., Lumley, M. A., Stracks, J. S., Clauw, D. J., & Williams, D. A. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1418-6 · Cited by 102
Namba, M. D., Leyrer-Jackson, J. M., Nagy, E. K., Olive, M. F., & Neisewander, J. L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.650785 · Cited by 76
“, 2016), reduces pain in women with fibromyalgia (Arnold et al., 2007; Bidari et al., 2019).”
BackgroundPregabalin: A Review of its Use in Fibromyalgia
Lyseng-Williamson, K. A., & Siddiqui, M. A. A. (2008) · Drugs · doi:10.2165/00003495-200868150-00009 · Cited by 50
Mechanisms and management of functional abdominal pain
Farmer, A. D., & Aziz, Q. (2014) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814540880 · Cited by 50
Duloxetine for the treatment of fibromyalgia
Wright, C. L., Mist, S. D., Ross, R. L., & Jones, K. D. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.64 · Cited by 43
Review: Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome
Gaman, A., Bucur, M. C., & Kuo, B. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08103656 · Cited by 12
“…serotonin is a neuromediator highly involved in cortical processes, its modulation is widely used in the treatment of mood disorders, anxiety and a variety of somatoform conditions such as fibromyalgia [Arnold et al. 2007], IBS [Spiller, 2007], and functional dyspepsia [Harasiuk et al. 2007].”
Metadata
- Authors
- Arnold, L. M., Pritchett, Y. L., D'Souza, D. N., Kajdasz, D. K., Iyengar, S., & Wernicke, J. F.
- Venue
- Journal of Women's Health
- Publisher
- SAGE Publications
- Published
- 2007-10
- Volume
- 16
- Issue
- 8
- Pages
- 1145-1156
- ISSN
- 1059-7115 (ISSN-L)
- 1540-9996
- 1931-843X
- OpenAlex
- W2014425120
- Cited by
- 230
- References
- 7
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.